NVF IPO Exits: Our successes
Since its foundation in 1996, the Novartis Venture Fund has actively supported nearly 40 of its portfolio companies to access the public capital markets like the NASDAQ through a variety of transactions including initial public offerings, as well as reverse mergers, some of which resulted in subsequent acquisitions by large international pharmaceutical companies.
The list of NVF IPO exits
Acorda Therapeutics
Acorda Therapeutics completed its initial public offering (NASDAQ: ACOR) in 2006.
Aeglea Biotherapeutics
Aeglea Biotherapeutics completed its initial public offering (NASDAQ: AGLE) in 2016.
Aerpio Therapeutics
Aerpio Therapeutics completed its initial public offering (NASDAQ:ARPO) in 2017.
Aileron Therapeutics
Aileron Therapeutics completed its initial public offering (NASDAQ) in 2017.
Akebia Therapeutics
Akebia Therapeutics completed its initial public offering (NASDAQ: AKBA) in 2014.
Akouos
Akouos completed its initial public offering (NASDAQ: AKUS) in 2020 and was acquired by Lilly in 2022.
Altimmune, Inc.
Altimmune, Inc. completed a reverse merger into PharmAthene, Inc. (NASDAQ: ALT) and became publicly listed in 2017.
Annexon
Annexon completed its initial public offering (NASDAQ:ANNX) in 2020.
Adicet Bio
Adicet Bio completed a reverse merger into resTORbio and became publicly listed (NASDAQ: ACET) in 2020.
Bicycle Therapeutics
Bicycle Therapeutics completed its initial public offering (NASDAQ: BCYC) in 2019.
BioNano Genomics
BioNano Genomics completed its initial public offering (NASDAQ: BNGO) in 2018.
Celladon
Celladon completed its initial public offering (NASDAQ: CLDN) in 2014.
Cellerix
Cellerix completed a reverse merger into Tigenix BV and became publicly listed (NYSE: TIG) in 2011.
CombinatorRx
CombinatorRx completed its initial public offering (NASDAQ: CRXX) in 2005.
Cytos Biotechnology
Cytos Biotechnology completed its initial public offering (SWX: CYTN) in 2002.
Evolva Holding
Evolva Holding completed a reverse merger into Arpida AG and became publicly listed (SIX: EVE) in 2010.
Eyetech Pharmaceuticals
Eyetech Pharmaceuticals completed its public offering (NASDAQ: EYET) in 2004 and was acquired by Valeant in 2012.
Forma Therapeutics
Forma Therapeutics completed its initial public offering (NASDAQ: FMTX) in 2020 and was acquired by Novo Nordisk in 2022.
Galera Therapeutics
Galera Therapeutics completed its initial public offering (NASDAQ:GRTX) in 2019.
Gensight Biologics
Gensight Biologics completed its initial public offering (Euronext) in 2016.
Idenix Pharmaceuticals
Idenix Pharmaceuticals completed its initial public offering (NASDAQ: IDIX) in 2004 and was acquired by Merck in 2014.
Infinity Pharmaceuticals
Infinity Pharmaceuticals completed a reverse merger into Discovery Partners, Inc. and became publicly listed (NASDAQ: INFI) in 2006.
IsoTis OrthoBiologics
IsoTis OrthoBiologics completed its initial public offering (SWX: ISON) in 2000.
Merus
Merus completed its initial public offering ((NASDAQ) in 2016.
Nabriva
Nabriva completed its initial public offering (NASDAQ: NBRV) in 2015.
Neovacs
Neovacs completed its initial public offering (Alternext Paris: ALNEV) in 2010.
Oculis
Oculis completed a merger with EBAC, a Special Purpose Acquisition Company, and became publicly listed (NASDAQ: OCS) in 2023.
PharmAbcine
PharmAbcine Inc. completed its initial public offering (KOSDAQ) in 2018.
Qurient
Qurient completed its initial public offering (KOSDAQ: 115180) in 2016.
Ra Pharmaceuticals
Ra Pharmaceuticals completed its initial public offering (NASDAQ: RARX) in 2016 and was acquired by UCB in 2019.
Renovacor
Renovacor completed a public listing via a merger with Chardan Healthcare Acquisition 2 Corp., a Special Purpose Acquisition Company, became publicly listed (NASDAQ: RCOR) in 2021 and was acquired by Rocket Pharmaceuticals in 2022.
Silence Therapeutics
Silence Therapeutics completed its initial public offering (LON: SLN) in 2005.
Sirtris Pharmaceuticals
Sirtris Pharmaceuticals completed its initial public offering (NASDAQ: SIRT) in 2007 and was acquired by GlaxoSmithKline in 2008.
Speedel Holding
Speedel Holding completed its initial public offering (SWX: SPPN) in 2005 and was acquired by Novartis in 2008.
Theravance
Theravance completed its initial public offering (NASDAQ: THRX) in 2004.
Tokai Pharmaceuticals
Tokai Pharmaceuticals completed its initial public offering (NASDAQ: TKAI) in 2014.
Torrey Pines Therapeutics
Torrey Pines Therapeutics completed a reverse merger into Axonyx and became publicly listed (NASDAQ: TPTX) in 2006.
Tscan
Tscan completed its initial public offering (NASDAQ:TCRX) in 2021.
Xenoport
Xenoport completed its initial public offering (NASDAQ: XNPT) in 2005.
Our investment team has proven experience
With successful backgrounds in medicine, science, legal, investment, and business development, our team has expertise in bringing exciting new drugs and treatments to patients all over the world.
Learn about our achievements in M&A
The NVF team has developed exit strategies that have steered 29 life science companies, so far, to successful mergers and acquisitions.